In the battle for weight-loss supremacy, Hims & Hers Health has emerged as a dark horse candidate shaking up the market.

Oprah Winfrey and Elon Musk endorsed it. And though Indian celebrities haven’t yet admitted to their use, the mystery ...

Eye Surgeon, LASIK specialist, Retina Specialist, and Director, Surya Eye Hospital, sheds light on India’s burgeoning interest in diabetes medication like Ozempic, Wegovy etc, highlighting both opport ...

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its ...

A federal judge in Texas has upheld the U.S. Food and Drug Administration's decision to remove Novo Nordisk's blockbuster ...

U.S. District Judge Mark Pittman in Fort Worth, Texas, reportedly upheld the U.S. Food and Drug Administration's (FDA) ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.

TD Cowen reiterated its Buy rating and $105.00 price target on Novo Nordisk (NYSE: NVO) Wednesday following meetings with the company’s senior leadership in Copenhagen. The pharmaceutical giant, with ...

Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.